What is the risk of using an opioid agonist-antagonist like Stadol for a client previously on opioids?

Using an opioid agonist-antagonist like Stadol in a client who has previously been on opioids carries the significant risk of triggering withdrawal symptoms. This occurs because these medications can occupy the same receptors as traditional opioids but do not activate them to the same extent. If the client has developed a tolerance or physical dependence on full agonist opioids, switching to an agonist-antagonist can abruptly block the action of the full agonist drugs present in the body, leading to withdrawal symptoms.

Withdrawal symptoms can include anxiety, sweating, shaking, insomnia, and increased pain, among others. This is particularly concerning for clients who may already be in a compromised state due to their previous opioid use. Recognizing this risk is crucial in preventing unnecessary discomfort and ensuring the safety and efficacy of pain management strategies.